ASCO 2021 | Preoperative CRT improves overall survival in pancreatic cancer: long-term results of PREOPANC

Casper H. Van Eijck, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, discusses the long-term results of a multicenter, randomized, Phase III trial evaluating preoperative chemoradiotherapy (CRT) in patients with resectable and borderline resectable pancreatic cancer. Preoperative gemictabine-based chemoradiation for pancreatic cancer demonstrated improved long-term overal survival when compared to immediate surgery with adjuvant gemcitabine. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.